Patent · US Active

RNAi inhibition of alpha-ENaC expression

US10544418B2 · kind B2 · utility

1Cited by

23References

13Claims

0Family size

Assignee

Arrowhead Pharmaceuticals, Inc. · US

Inventors

Gino Van Heeke · Gainesville, US
Emma Hickman · Horsham, GB
Henry Luke Danahay · Horsham, GB
Pamela Tan · Kulmbach, DE
Anke Geick · Bayreuth, DE
Hans-Peter Vornlocher · Bayreuth, DE

Key dates

Filing date	Jan 18, 2018
Grant date	Jan 28, 2020
Priority date	—
Expiry date	Jan 18, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.